Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Intermediate Risk Prostate Cancer: Feasibility Study
The hypothesis of this feasibility study is that focal treatment with ExAblate MRgFUS has
the potential to be a safe and effective non-invasive treatment for low to intermediate
risk, organ-confined prostate cancer involving low incidence of morbidity. The study
hypothesis will be tested by measuring treatment-related safety and initial effectiveness
parameters in the ExAblate MRgFUS treated patients, as described above.
Based on the result of this study, InSightec will initiate a larger study in an effort to
approve low risk, organ-confined prostate cancer as an indication for its ExAblate MRgFUS
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society